STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
A capital-markets-day reset for Novo landed alongside a meta-regression on GLP-1 stroke and cognitive outcomes.
TL;DR
- STAT reported that Novo Nordisk outlined a new strategy for obesity and direct-to-consumer work at its capital-markets day.
- STAT's Pharmalittle roundup noted Novo's plans to expand its pipeline alongside early Alkermes ADHD data.
- A medRxiv systematic review and meta-regression examined GLP-1 receptor agonists and stroke and cognitive outcomes, and ScienceDaily asked whether Ozempic can change your body — and your life.
STAT reported that Novo Nordisk outlined a new strategy for obesity and direct-to-consumer work at its capital-markets day. [1]
STAT's Pharmalittle roundup noted Novo's plans to expand its pipeline alongside early Alkermes ADHD data. [2]
On the research side, a medRxiv systematic review and meta-regression examined GLP-1 receptor agonists and stroke and cognitive outcomes, and ScienceDaily asked whether Ozempic can change your body — and your life. [3] [4]
Why it matters
GLP-1 coverage is becoming a mass-market reimbursement story, so the read-through runs from drugmakers to insurers and to the wider health-spending debate.
Editor's note
Company claims and early trial data are as reported by the outlets and were not independently reviewed; no medical or investment advice is offered.